Research programme: ROR vaccines - Kancera
Latest Information Update: 15 Aug 2016
At a glance
- Originator Kancera
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Receptor tyrosine kinase-like orphan receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Leukaemia
Most Recent Events
- 31 Mar 2016 Discontinued for Leukaemia in Sweden (unspecified route)